Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6297]

Study identifies immune switch critical to autoimmunity and cancer

Study identifies immune switch critical to autoimmunity and cancer

$SABCS 2025: Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for certain endocrine therapy-refractory advanced breast cancers$

SABCS 2025: Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for certain...

ASH 2025: Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

ASH 2025: Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers

ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers 

$ASH 2025: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or refractory multiple myeloma$

ASH 2025: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or...

ASH 2025: Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

ASH 2025: Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially preventable

ASH 2025: Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially...

Triaptosis - an emerging paradigm in cancer therapeutics

Triaptosis - an emerging paradigm in cancer therapeutics

Could altering the daily timing of immunotherapy improve survival in people with cancer?

Could altering the daily timing of immunotherapy improve survival in people with cancer?

More from ecancer